Jakob Klemm, Shahrokh F Shariat, Ekaterina Laukhtina, Pawel Rajwa, Malte W Vetterlein, Victor M Schuettfort, Markus von Deimling, Roland Dahlem, Margit Fisch, Michael Rink
INTRODUCTION AND OBJECTIVES: We examined the impact of preoperative plasma potassium levels (PPLs) on outcomes in patients undergoing radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB), hypothesizing that potassium imbalances might influence outcomes. PATIENTS AND METHODS: In this retrospective study, 501 UCB patients undergoing RC from 2009 to 2017 at a tertiary center were analyzed. Blood samples collected a week prior to surgery defined normal and abnormal PPL based on institutional standards...
March 21, 2024: Clinical Genitourinary Cancer
Kazuhiro Matsumoto, Hirotaka Akita, Akinori Hashiguchi, Toshikazu Takeda, Takeo Kosaka, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya, Masahiro Jinzaki
PURPOSE: Prostate cancer generally occurs multifocally. The lesions of the largest size and highest-grade are often concordant, and defined as an index tumor. However, these factors sometimes do not coincide within one lesion. In such discordant cases, not the largest size lesion but the highest-grade lesion is known to determine the prognosis. We focused on the multiparametric magnetic resonance imaging (mpMRI) detectability of the highest-grade tumors in discordant cases. MATERIALS AND METHODS: We investigated the detectability of the highest-grade tumor using preoperative mpMRI in 50 discordant patients who underwent radical prostatectomy...
March 21, 2024: Clinical Genitourinary Cancer
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Maria Bassanelli, Melissa Bersanelli, Marilena Di Napoli, Michele Dionese, Martina Fanelli, Roberto Filippi, Giuseppe Fotia, Luca Galli, Francesco Grillone, Michele Maffezzoli, Brigida Anna Maiorano, Cecilia Nasso, Sara Elena Rebuzzi, Luca Lalli, Giandomenico Roviello, Mariella Sorarù, Bruno Vincenzi, Giuseppe Procopio, Elena Verzoni
BACKGROUND: Peritoneal metastases (PM) have been reported in approximately 1% of patients with metastatic Renal Cell Carcinoma (mRCC). Outcome data are limited due to the rarity of this metastatic site. Therefore, the aim of our study is to describe renal cell carcinoma (RCC) patients with PM treated as per clinical practice. MATERIALS AND METHODS: Baseline characteristics and outcome data of patients with PM from RCC were retrospectively collected from 18 Italian oncological referral centers adhering to the Meet-Uro group, from January 2016 to January 2023...
March 19, 2024: Clinical Genitourinary Cancer
Veronica Mollica, Francesco Massari, Marco Maruzzo, Davide Bimbatti, Melanie Claps, Brigida Anna Maiorano, Maria Giuseppa Vitale, Roberto Iacovelli, Paola Ermacora, Giandomenico Roviello, Fabio Calabrò, Orazio Caffo, Francesca Vignani, Francesco Grillone, Francesco Pierantoni, Marilena Di Napoli, Alessia Mennitto, Andrea Marchetti, Alvise Mattana, Alessia Cavo, Maria Bassanelli, Luigi Formisano, Veronica Prati, Giulia Claire Giudice, Sebastiano Buti
INTRODUCTION: Penile squamous cell carcinoma (PSCC) is a rare tumor with an aggressive behavior. The Meet-URO 23/I-RARE registry includes rare genitourinary malignancies. We extracted patients with PSCC to conduct a retrospective study aimed at assessing clinical outcomes and prognostic factors. PATIENTS AND METHODS: Primary endpoints were overall survival and progression-free survival. Prognostic factors for OS and PFS were analyzed using univariate and multivariate analysis...
March 18, 2024: Clinical Genitourinary Cancer
Hatime Arzu Yasar, Burak Yasin Aktas, Gokhan Ucar, Sema Sezgin Goksu, Irem Bilgetekin, Burcu Cakar, Abdullah Sakin, Ozturk Ates, Tugba Basoglu, Cagatay Arslan, Atike Gokcen Demiray, Semra Paydas, Irfan Cicin, Mehmet Ali Nahit Sendur, Nuri Karadurmus, Hakan Kosku, Aytuğ Uner, Perran Fulden Yumuk, Gungor Utkan, Umut Kefeli, Ozgur Tanriverdi, Havva Cinkir, Ozge Gumusay, Nazım Serdal Turhal, Serkan Menekse, Engin Kut, Ismail Beypinar, Teoman Sakalar, Hacer Demir, Emre Yekeduz, Saadettin Kilickap, Mustafa Erman, Yuksel Urun
INTRODUCTION: Adrenocortical carcinoma (ACC) is a rare yet highly malignant tumor associated with significant morbidity and mortality. This study aims to delineate the clinical features, survival patterns, and treatment modalities of ACC, providing insights into the disease's prognosis. MATERIALS AND METHODS: A retrospective analysis of 157 ACC patients was performed to assess treatment methodologies, demographic patterns, pathological and clinical attributes, and laboratory results...
March 15, 2024: Clinical Genitourinary Cancer
Syed Shariq Naeem, Pooja Gupta, Ranjit Kumar Sahoo, V L Kumar, T Velpandian, Archana Singh, Atul Batra, Raja Pramanik, Sameer Rastogi, Saumya Srivastava
INTRODUCTION: Hand foot skin reaction (HFSR) is a common dose-limiting adverse effect of multi kinase inhibitors (MKI) whose mechanism is not fully understood, and the prophylaxis is inadequate. OBJECTIVE: In this pilot study, a double-blind, randomized placebo-controlled trial was conducted to evaluate the effect of topical urea in secondary prevention of sunitinib-induced HFSR in renal cell cancer patients. METHODS: Out of 55 screened patients, 14 were randomized to receive topical urea or placebo for four weeks...
March 13, 2024: Clinical Genitourinary Cancer
Hamed Bagheri, Seyed Rabi Mahdavi, Parham Geramifar, Ali Neshasteh-Riz, Masoumeh Sajadi Rad, Habibollah Dadgar, Hossein Arabi, Habib Zaidi
The objective of this work was to review comparisons of the efficacy of 68 Ga-PSMA-11 (prostate-specific membrane antigen) PET/CT and multiparametric magnetic resonance imaging (mpMRI) in the detection of prostate cancer among patients undergoing initial staging prior to radical prostatectomy or experiencing recurrent prostate cancer, based on histopathological data. A comprehensive search was conducted in PubMed and Web of Science, and relevant articles were analyzed with various parameters, including year of publication, study design, patient count, age, PSA (prostate-specific antigen) value, Gleason score, standardized uptake value (SUVmax ), detection rate, treatment history, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and PI-RADS (prostate imaging reporting and data system) scores...
March 13, 2024: Clinical Genitourinary Cancer
Matthew Young, Jose C Tapia, Bernadett Szabados, Agne Jovaisaite, Francesca Jackson-Spence, Elizabeth Nally, Thomas Powles
BACKGROUND: Reliable biomarkers in renal cell carcinoma (RCC) remain elusive. While several markers have been shown to be associated with prognosis, and may aid in risk assessment, predictive biomarkers of response to immune checkpoint inhibitors (ICIs) have not been established. Previous studies have shown that a high pretreatment neutrophil-lymphocyte ratio (NLR) is a negative prognostic factor in RCC. However, a clinically useful cut-off for the predictive and prognostic value of NLR has not been well defined...
March 8, 2024: Clinical Genitourinary Cancer
Susu Zhou, Parissa Alerasool, Noriko Kishi, Himanshu Joshi, Gagan Sahni, Che-Kai Tsao
INTRODUCTION: Second-generation androgen receptor axis-targeting (ARAT) agents have become a standard treatment for patients with advanced prostate cancer (PC), however much remains unknown about the potential cardiovascular toxicities. PATIENTS AND METHODS: We performed a systematic search of PubMed, Embase, Web of Science, and Cochrane library for randomized controlled trials of patients receiving ARAT agents for PC from inception to March 2023. The odds ratios (ORs) of all-grade and high-grade cardiovascular adverse events (CVAEs) for patients treated with and without ARAT agents were pooled for meta-analysis...
March 8, 2024: Clinical Genitourinary Cancer
Cagri Akpinar, Digdem Kuru Oz, Alkan Oktar, Evren Suer, Eriz Ozden, Nuray Haliloglu, Omer Gulpinar, Mehmet Ilker Gokce, Cagatay Gogus, Sumer Baltaci
INTRODUCTION: Recent guidelines suggest that biopsy may be omitted in some groups of patients with PI-RADS 3 lesions on mpMRI. In this study, we aimed to evaluate biopsy strategies involving prostate-specific antigen density (PSAd) to avoid unnecessary biopsy versus the risk of missing clinically significant prostate cancer (csPCa) in patients with PI-RADS 3 lesions. MATERIAL AND METHODS: Data of 616 consecutive patients who underwent PSAd and mpMRI before prostate biopsy between January 2017 and January 2022 at a single center were retrospectively assessed...
March 8, 2024: Clinical Genitourinary Cancer
Jakob N Henriksen, Charlotte U Andersen, Niels Fristrup
Inter-individual variability in drug response pose significant challenges to treatment with tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC). TKIs meet traditional criteria for using therapeutic drug monitoring (TDM), but research is still limited. Understanding the role of TDM in individualizing treatment strategies could help optimize treatment. Here we review the state of knowledge of TDM for TKIs in mRCC treatment. A comprehensive literature review of original research studies focusing on TDM of TKIs in mRCC treatment, clinical in vivo studies reporting on pharmacokinetics-pharmacodynamics, therapeutic ranges, drug concentrations, dose adjustments, clinical outcomes, or other relevant aspects related to TDM...
March 8, 2024: Clinical Genitourinary Cancer
Kong Ren, Hao Ning, Hai-Hu Wu, Fei Wu, Jia-Ju Lyu
BACKGROUND: Although a survival benefit was observed in patients with metastatic renal cell carcinoma (mRCC) who underwent cytoreductive nephrectomy (CN), there is a lack of effective tools for predicting which individuals are likely to benefit from surgical intervention. Herein, we developed a predictive model using data from the Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: Patients diagnosed with mRCC were screened from the SEER database (2010-2020), supplemented by patients from East Asia...
March 6, 2024: Clinical Genitourinary Cancer
Robert H Mbilinyi, Pavlos Msaouel, Priya Rao, Jose A Karam, Nizar M Tannir, Chad Tang
No abstract text is available yet for this article.
March 5, 2024: Clinical Genitourinary Cancer
Inkeun Park, Jungyo Suh, Bumjin Lim, Cheryn Song, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Yong Mee Cho, Jaelyun Lee, Bumsik Hong
PURPOSE: The study aimed to investigate the impact of adjuvant chemotherapy on time to recurrence (TTR) and overall survival (OS) in patients with histologic variants of upper tract urothelial carcinoma (VUTUC) following radical nephroureterectomy (RNU). MATERIALS AND METHODS: A retrospective review of 131 VUTUC patients' medical records, from a pool of 368 non-metastatic localized or locally advanced UTUC cases, treated at a single tertiary referral center between January 2011 and January 2021...
March 4, 2024: Clinical Genitourinary Cancer
Marc Walsh, Asia Jordan, Lea Schäfer, Jana Joha, Ben Heapes, Megan Noonan, William Gallagher, Hubert Gallagher, Rustom P Manecksha, David Galvin, Greg Nason, Terri Martin, Ciara Lyons, Robert O'Connor, Frances J Drummond, Claire Kilty, Antoinette S Perry
BACKGROUND: Our understanding of patient experiences with prostate cancer testing for diagnosis and surveillance is limited. The aim of this study was to collaborate with patients and clinicians to understand their lived experience and unmet needs around the early detection, diagnosis and monitoring (active surveillance) of prostate cancer. METHODS: Two focus groups were held with patients (n = 20) and healthcare professionals (n = 16), to identify the main challenges in prostate cancer detection, diagnosis, and monitoring...
March 4, 2024: Clinical Genitourinary Cancer
Zuzana Orszaghova, Dominika Galikova, Peter Lesko, Jana Obertova, Katarina Rejlekova, Zuzana Sycova-Mila, Patrik Palacka, Katarina Kalavska, Daniela Svetlovska, Beata Mladosievicova, Jozef Mardiak, Michal Mego, Michal Chovanec
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) after curative treatment for testicular germ cell tumors (GCTs) has been previously reported. It has been shown that CIPN can contribute to impaired quality of life (QOL) in cancer survivors. Herein, we aimed to evaluate CIPN in association with QOL in GCT survivors. PATIENTS AND METHODS: European Organization for Research and Treatment of Cancer (EORTC) Quality of Life - Chemotherapy-Induced Peripheral Neuropathy questionnaire (QLQ-CIPN20) and Quality of Life Questionnaire (QLQ-C30) were prospectively completed by GCT survivors (N = 151) at National Cancer Institute in Slovakia during their annual follow-up...
March 2, 2024: Clinical Genitourinary Cancer
Dengxiong Li, Ruicheng Wu, Jie Wang, Junjiang Ye, Qingxin Yu, Dechao Feng, Ping Han
BACKGROUND: There is an urgent need to identify a robust predictor for BCG response in patients with non-muscle-invasive bladder cancer (NMIBC). We aimed to employ the Lasso regression model for the selection and construction of an index (BCGI) utilizing inflammation and nutrition indicators to predict the response to BCG therapy. METHODS: After acquiring the ethics approval, we searched the electric medical records in our institution and performed data screening...
February 29, 2024: Clinical Genitourinary Cancer
Jazzmyne Montgomery, Daniel Lybbert, Sherjeel Sana, Ahmed El-Zawahry, James Peabody, Tiffany Pearce, Nicole Adams, Mustafa Deebajah, Danuta Dynda, Kara Babaian, Jane Crabtree, Kristin Delfino, Kevin McVary, Kathy Robinson, Krishna Rao, Shaheen Alanee
OBJECTIVE: To report urinary bother, urinalysis changes, disease-free survival (DFS), and overall survival (OS) over 2 years for subjects enrolled in a phase I dose-escalation trial (NCT02324582) of intravesical Bacillus Calmette-Guérin (BCG) in combination with systemic pembrolizumab for recurrent or persistent high-grade non-muscle invasive bladder cancer (HGNMIBC). METHODS: Eighteen patients consented to the study. Five were screen failures. Clinical activity was determined using cystoscopy and cytology with a biopsy of suspicious lesions...
February 28, 2024: Clinical Genitourinary Cancer
Frederick Okoye, Adam J Gadzinski, Rishi Sekar, Isabelle Abarro, Petros Grivas, Scott S Tykodi, Jay Liao, Jonathan Chen, Jing Zeng, Jonathan Wright, John L Gore
BACKGROUND: We rapidly implemented a telemedicine Multidisciplinary Urologic Cancer Clinic (MDUCC) at the University of Washington/Seattle Cancer Care Alliance during the peak of the COVID-19 Public Health Emergency to maintain our ability to provide multidisciplinary cancer care. We report our experiences though assessment of patient-reported outcomes from our telemedicine MDUCC. METHODS: Video visits with a urologic oncologist, medical oncologist, and radiation oncologist were conducted in the same format as our in-person MDUCC...
February 24, 2024: Clinical Genitourinary Cancer
Jeffrey Graham, Sunita Ghosh, Rodney H Breau, Lori Wood, Simon Tanguay, Dominick Bosse, Aly-Khan Lalani, Bimal Bhindi, Daniel Heng, Antonio Finelli, Nazanin Fallah-Rad, Vincent Castonguay, Naveen S Basappa, Denis Soulières, Frédéric Pouliot, Christian Kollmannsberger, Georg A Bjarnason
BACKGROUND: Cabozantinib, an oral multi-targeted tyrosine kinase inhibitor (TKI), has demonstrated efficacy in metastatic renal cell carcinoma (mRCC). The association between toxicity and therapeutic effectiveness has been established with other TKIs. We investigated whether cabozantinib dose reductions, a surrogate for toxicity and adequate drug exposure, were associated with improved clinical outcomes in mRCC. METHODS: Employing the CKCis database, we analyzed patients treated with cabozantinib in the second line or later between 2011 to 2021...
February 23, 2024: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.